Recursion Pharmaceuticals-a Share Price (NASDAQ: RXRX)

$4.7

▲

-0.17

(-3.49%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Recursion Pharmaceuticals-a Stock chart to analyse performance

Recursion Pharmaceuticals-a stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$4.64
Today's High:$4.84
$4.70
1.38%
Downside
Day's Volatility :4.24%
Upside
2.89%
52 Weeks Low:$3.79
52 Weeks High:$12.36
$4.70
19.36%
Downside
52 Weeks Volatility :69.34%
Upside
61.97%

Recursion Pharmaceuticals-a Stock Returns

Period	Recursion Pharmaceuticals-a	Sector (Health Care)	Index (Russel 2000)
3 Months	7.44%	3.6%	0.0%
6 Months	-28.76%	-7.7%	0.0%
1 Year	-35.51%	-12.6%	0.0%
3 Years	-55.33%	9.5%	-4.7%

Recursion Pharmaceuticals-a Key Stats

Check Recursion Pharmaceuticals-a key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$4.87
Open	$4.85
Today's High	$4.84
Today's Low	$4.635
Market Capitalization	$2.1B
Today's Volume	$15.1M
52 Week High	$12.36
52 Week Low	$3.79
Revenue TTM	$64.6M
EBITDA	$-586.4M
Earnings Per Share (EPS)	$-1.81
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-86.34%

Stock Returns calculator for Recursion Pharmaceuticals-a Stock including INR - Dollar returns

The Recursion Pharmaceuticals-a stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Recursion Pharmaceuticals-a investment value today

Current value as on today

₹69,845

Returns

₹30,155

(-30.16%)

Returns from Recursion Pharmaceuticals-a Stock

₹35,440 (-35.44%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Recursion Pharmaceuticals-a Stock

-36.36%

Period: Jul 30, 2025 to Aug 29, 2025. Change in 30 Days versus previous period

Investment in Recursion Pharmaceuticals-a Shares from India has dropped by -36.36% over the past 30 days, indicating reduced transactional activity.

-52%

Period: Jul 30, 2025 to Aug 29, 2025. Change in 30 Days versus previous period

Search interest for Recursion Pharmaceuticals-a Stock from India on INDmoney has decreased by -52% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Recursion Pharmaceuticals-a

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
8.31%
ARK Investment Management LLC
7.60%
Baillie Gifford & Co Limited.
5.57%
BlackRock Inc
5.41%
SoftBank Group Corp
3.38%
State Street Corp
3.01%

Analyst Recommendation on Recursion Pharmaceuticals-a Stock

Rating

Trend

Buy

53%Buy

46%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Recursion Pharmaceuticals-a(by analysts ranked 0 to 5 stars)

Recursion Pharmaceuticals-a Share Price Target

What analysts predicted

Upside of 37.59%

Target:

$6.47

Current:

$4.70

Recursion Pharmaceuticals-a share price target is $6.47, a slight Upside of 37.59% compared to current price of $4.70 as per analysts' prediction.

Recursion Pharmaceuticals-a Stock Insights

Price Movement
In the last 1 month, RXRX stock has moved down by -19.2%
Increasing Revenue
Revenue is up for the last 3 quarters, 4.51M → 19.10M (in $), with an average increase of 46.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -202.48M → -171.89M (in $), with an average increase of 17.8% per quarter
RXRX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 105.4%
RXRX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 165.6%
Price to Sales
ForRXRX every $1 of sales, investors are willing to pay $26.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Recursion Pharmaceuticals-a Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$1.7M	-
Net Income	$-62.5M	-
Net Profit Margin	-3.7K%	-

	FY20	Y/Y Change
Revenue	$3.4M	↑ 99.47%
Net Income	$-87.9M	↑ 40.55%
Net Profit Margin	-2.6K%	↑ 1079.38%

	FY21	Y/Y Change
Revenue	$10.0M	↑ 193.0%
Net Income	$-178.1M	↑ 102.63%
Net Profit Margin	-1.8K%	↑ 794.18%

	FY22	Y/Y Change
Revenue	$39.7M	↑ 296.81%
Net Income	$-239.4M	↑ 34.45%
Net Profit Margin	-603.36%	↑ 1177.38%

	FY23	Y/Y Change
Revenue	$44.6M	↑ 12.33%
Net Income	$-328.1M	↑ 37.02%
Net Profit Margin	-735.99%	↓ 132.63%

	FY24	Y/Y Change
Revenue	$58.8M	↑ 32.0%
Net Income	$-463.7M	↑ 41.33%
Net Profit Margin	-788.02%	↓ 52.03%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$13.8M	↑ 26.66%
Net Income	$-91.4M	↓ 1.75%
Net Profit Margin	-662.41%	↑ 191.47%

	Q2 FY24	Q/Q Change
Revenue	$14.4M	↑ 4.52%
Net Income	$-97.5M	↑ 6.75%
Net Profit Margin	-676.56%	↓ 14.15%

	Q3 FY24	Q/Q Change
Revenue	$26.1M	↑ 80.91%
Net Income	$-95.7M	↓ 1.91%
Net Profit Margin	-366.82%	↑ 309.74%

	Q4 FY24	Q/Q Change
Revenue	$4.5M	↓ 82.7%
Net Income	$-178.9M	↑ 86.99%
Net Profit Margin	-4.0K%	↓ 3599.17%

	Q1 FY25	Q/Q Change
Revenue	$14.7M	↑ 226.87%
Net Income	$-202.5M	↑ 13.18%
Net Profit Margin	-1.4K%	↑ 2592.73%

	Q2 FY25	Q/Q Change
Revenue	$19.1M	↑ 29.56%
Net Income	$-171.9M	↓ 15.11%
Net Profit Margin	-899.84%	↑ 473.42%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-44.1M	-

	FY20	Y/Y Change
Profit	$-59.9M	↑ 35.85%

	FY21	Y/Y Change
Profit	$10.0M	↓ 116.69%

	FY22	Y/Y Change
Profit	$-8.6M	↓ 185.94%

	FY23	Y/Y Change
Profit	$2.0M	↓ 123.13%

	FY24	Y/Y Change
Profit	$13.6M	↑ 584.15%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-772.0K	↓ 93.87%

	Q2 FY24	Q/Q Change
Profit	$1.3M	↓ 270.73%

	Q3 FY24	Q/Q Change
Profit	$14.0M	↑ 962.44%

	Q4 FY24	Q/Q Change
Profit	$-8.3M	↓ 159.15%

	Q1 FY25	Q/Q Change
Profit	$-7.1M	↓ 14.48%

	Q2 FY25	Q/Q Change
Profit	$-1.1M	↓ 85.06%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-57.0M	-
Investing Cash Flow	$-3.9M	-
Financing Cash Flow	$120.4M	-

	FY20	Y/Y Change
Operating Cash Flow	$-45.4M	↓ 20.41%
Investing Cash Flow	$-8.7M	↑ 123.53%
Financing Cash Flow	$246.1M	↑ 104.41%

	FY21	Y/Y Change
Operating Cash Flow	$-158.6M	↑ 249.38%
Investing Cash Flow	$-271.7M	↑ 3009.2%
Financing Cash Flow	$458.5M	↑ 86.3%

	FY22	Y/Y Change
Operating Cash Flow	$-83.5M	↓ 47.34%
Investing Cash Flow	$193.2M	↓ 171.11%
Financing Cash Flow	$154.3M	↓ 66.34%

	FY23	Y/Y Change
Operating Cash Flow	$-287.8M	↑ 244.55%
Investing Cash Flow	$-10.2M	↓ 105.29%
Financing Cash Flow	$140.1M	↓ 9.21%

	FY24	Y/Y Change
Operating Cash Flow	$-359.2M	↑ 24.81%
Investing Cash Flow	$260.1M	↓ 2642.62%
Financing Cash Flow	$304.1M	↑ 117.02%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-102.3M	↑ 38.1%
Investing Cash Flow	$-6.7M	↑ 167.4%
Financing Cash Flow	$13.9M	↓ 82.77%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-82.2M	↓ 19.63%
Investing Cash Flow	$-4.2M	↓ 37.14%
Financing Cash Flow	$263.1M	↑ 1793.37%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-59.2M	↓ 27.97%
Investing Cash Flow	$-4.6M	↑ 9.09%
Financing Cash Flow	$16.5M	↓ 93.74%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-115.4M	↑ 94.9%
Investing Cash Flow	$275.5M	↓ 6138.05%
Financing Cash Flow	$10.6M	↓ 35.37%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-132.0M	↑ 14.32%
Investing Cash Flow	$-7.3M	↓ 102.64%
Financing Cash Flow	$40.5M	↑ 280.93%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-76.4M	↓ 42.09%
Investing Cash Flow	$-5.8M	↓ 20.11%
Financing Cash Flow	$97.7M	↑ 140.97%

Recursion Pharmaceuticals-a Technicals Summary

Sell

Neutral

Buy

Recursion Pharmaceuticals-a is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Recursion Pharmaceuticals-a Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Recursion Pharmaceuticals-a	-21.09%	-28.76%	-35.51%	-55.33%	-83.51%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.98%	-0.05%	-6.32%
Beone Medicines Ltd	1.77%	24.81%	59.79%	78.52%	26.86%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-21.18%	38.72%	40.03%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	69.91%	115.96%	236.5%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Recursion Pharmaceuticals-a	NA	NA	NA	-1.58	-0.86	-0.39	NA	2.12
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Recursion Pharmaceuticals-a	Buy	$2.1B	-83.51%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-6.32%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	26.86%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	40.03%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	236.5%	NA	-12.96%

Recursion Pharmaceuticals-a Dividend announcements

Recursion Pharmaceuticals-a Earnings
Recursion Pharmaceuticals-a’s price-to-earnings ratio stands at None

About Recursion Pharmaceuticals-a

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Organization	Recursion Pharmaceuticals-a
Employees	800
CEO	Dr. Christopher C. Gibson Ph.D.
Industry	Services

Key Management of Recursion Pharmaceuticals-a

Name	Title
Dr. Christopher C. Gibson Ph.D.	Co-Founder, CEO & Director
Mr. Ben R. Taylor	CFO & President of Recursion UK
Dr. David J. Mauro M.D., Ph.D.	Chief Medical Officer
Dr. Najat Khan Ph.D.	Chief R&D Officer, Chief Commercial Officer and Director
Ms. Kristen Rushton M.B.A.	Chief Operating Officer
Kevin Leggat	Vice President of Finance & Accounting
Mr. Benjamin Mabey M.S.	Chief Technology Officer
Dr. David Hallett Ph.D.	Chief Scientific Officer
Mr. Nathan Hatfield J.D., M.B.A.	Chief Legal Officer & General Counsel
Ms. Erica Fox	Chief People and Impact Officer

Important FAQs about investing in RXRX Stock from India :

What is Recursion Pharmaceuticals-a share price today?

Recursion Pharmaceuticals-a share price today is $4.70 as on August 30, 2025 at 1:29 am IST at the close of the market. Recursion Pharmaceuticals-a share today touched a day high of $4.84 and a low of $4.64.

What is the 52 week high and 52 week low for Recursion Pharmaceuticals-a share?

Recursion Pharmaceuticals-a share touched a 52 week high of $12.36 and a 52 week low of $3.79. Recursion Pharmaceuticals-a stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $4.70, lower by 61.97% versus the 52 week high.

How to invest in Recursion Pharmaceuticals-a Stock (RXRX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Recursion Pharmaceuticals-a on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Recursion Pharmaceuticals-a Shares that will get you 0.3191 shares as per Recursion Pharmaceuticals-a share price of $4.70 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Recursion Pharmaceuticals-a Stock (RXRX) from India?

Indian investors can start investing in Recursion Pharmaceuticals-a (RXRX) shares with as little as ₹88.286 or $1 (as of August 30, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Recursion Pharmaceuticals-a stock (as per the Rupee-Dollar exchange rate as on August 30, 2025). Based on Recursion Pharmaceuticals-a share’s latest price of $4.70 as on August 30, 2025 at 1:29 am IST, you will get 2.1277 shares of Recursion Pharmaceuticals-a. Learn more about fractional shares .

What are the returns that Recursion Pharmaceuticals-a has given to Indian investors in the last 5 years?

Recursion Pharmaceuticals-a stock has given -83.51% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?